Last Updated on December 24, 2023 by The Health Master
The US Food and Drug Administration (USFDA) has given the final approval to Alembic Pharma’s Paclitaxel injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) multiple-dose vials, a statement from Alembic pharma notified yesterday.
According to the statement, this is the first product approval for oncology injection from our F-2 Facility (oncology injectable) which recently completed the first USFDA inspection.
Further, the statement said that the approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Taxol injection, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL).
Paclitaxel injection is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary.
As first-line therapy, it is indicated in combination with cisplatin for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy, added the statement.
In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors.
Paclitaxel injection has an estimated market size of $26 million for 12 months ending June 2022, according to IQVIA, the statement concluded.
USFDA gives approval to this Blood Cancer therapy
USFDA grants final approval for Micafungin for injection
USFDA gives tentative approval for Valbenazine capsules
USFDA gives nod for Extended Phenytoin Sodium Capsules
USFDA gives final approval for Brivaracetam tablets
This State Pharmacy Council to appoint Pharmacy Inspectors
Medical Stores पर कार्रवाई: नशीली दवाई बेचने पर Licenses cancel, suspend
Two persons arrested in fake BP medicine racket
NPPA extends time limit for submission of data of Drugs & Medical Devices
USFDA gives approval to this Blood Cancer therapy
NPPA fixes retail price for diabetes drug combination Dapagliflozin & Sitagliptin
USFDA grants final approval for Micafungin for injection
DTAB ratifies Rule 46 of Medical Devices Rules, 2017
Dove shampoos recalled due to this reason
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
